EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serum neurofilament light chain: a novel biomarker for cardiovascular diseases in individuals without hypertension

Jing Liu, Ya Zhang

Scientific Reports · 2024

DOI: 10.1038/s41598-024-77446-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Jing Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, The Affiliated Second Hospital, Hengyang Medical school, University of South China, Hengyang, 421009, China. Hauptthemen laut MEDLINE: Biomarkers, Cardiovascular Diseases, Hypertension, Neurofilament Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Serum neurofilament light chain (sNFL) is a biomarker for axonal injury. Previous studies have linked sNFL levels to cardiovascular risk factors such as diabetes and hypertension, but its association with cardiovascular diseases (CVD) remains unclear. This study aims to explore the association between sNFL and CVD and evaluates its predictive value. Utilizing NHANES 2013-2014 data, this study included 2,035 participants aged ≥ 20 years with measured sNFL quantified using a Siemens immunoassay. CVD was self-reported and included myocardial infarction, stroke, heart failure, coronary heart disease, or angina. Logistic regression models assessed the association between sNFL levels and CVD. The predictive value of sNFL for CVD was evaluated using area under the curve (AUC) and DeLong test. Participants with higher sNFL levels were typically older, male, non-Hispanic white, smokers, and had lower socioeconomic status, higher CVD, hypertension, and diabetes prevalence. Higher sNFL levels were significantly associated with increased odds of CVD (adjusted OR = 1.41, 95% CI: 1.05-1.88). The association was significant in non-hypertensive individuals (OR = 2.72, 95% CI: 1.61-4.62) but not in hypertensive individuals (OR = 1.13, 95% CI: 0.81-1.56). sNFL addition to traditional risk models improved predictive accuracy, especially in non-hypertensive individuals (AUC from 0.827 to 0.856). sNFL levels are significantly associated with CVD in the general population, with a strong predictive value in non-hypertensive individuals. Future longitudinal studies should validate sNFL's efficacy in various populations and explore the underlying mechanisms of its relationship with hypertension and CVD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersCardiovascular DiseasesHypertensionNeurofilament ProteinsHumansMaleFemaleMiddle AgedAdultAgedRisk Factors

Stichwörter der Autor:innen

Cardiovascular diseaseCardiovascular riskNHANESRisk predictionSerum neurofilament light chain

Substanzen

BiomarkersNeurofilament Proteinsneurofilament protein L

Autor:innen und Institutionen

  • Department of Emergency Medicine, The Affiliated Second Hospital, Hengyang Medical school, University of South China, Hengyang, 421009, China.
  • , No. 35 Jiefang Avenue, Zhengxiang District, Hengyang City, 421001, Hunan Province, PR China.
  • Department of Gland Surgery, The Affiliated Nanhua Hospital, Hengyang Medical school, University of South China, Hengyang, 421002, China. 15575625260@163.com.

Zitieren

APA

Liu, J., & Zhang, Y. (2024). Serum neurofilament light chain: a novel biomarker for cardiovascular diseases in individuals without hypertension. Scientific Reports. https://doi.org/10.1038/s41598-024-77446-y

Vancouver

Liu J, Zhang Y. Serum neurofilament light chain: a novel biomarker for cardiovascular diseases in individuals without hypertension. Scientific Reports. 2024. doi:10.1038/s41598-024-77446-y

BibTeX
@article{Liu2024,
  author = {Liu, Jing and Zhang, Ya},
  title = {Serum neurofilament light chain: a novel biomarker for cardiovascular diseases in individuals without hypertension},
  journal = {Scientific Reports},
  year = {2024},
  doi = {10.1038/s41598-024-77446-y}
}
Kostenlos starten →